Document is current
Any future updates will be listed below
-
Authors
Hamid, Omid
Piha-Paul, Sarina A
Liu, Stephen V
Boccia, Ralph
Call, Justin A
Wise-Draper, Trisha M
Alistar, Angela Tatiana
Olszanski, Anthony J
Wrangle, John
Shields, Anthony F
Manzano, Aranzazu
Calvo, Emiliano
Asha, Shwetha
Du, Yangchun
Mayo, Carlos
Rider, Leah
Ernstoff, Marc S
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03861793 at ClinicalTrials.govnct04592653 at ClinicalTrials.govDocuments that mention this clinical trial
ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy
https://doi.org/10.1136/jitc-2020-000673
724 Subcutaneous nemvaleukin alfa in combination with pembrolizumab in patients with refractory solid tumors (ARTISTRY-2)
https://doi.org/10.1136/jitc-2023-sitc2023.0724
34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019): part 1
https://doi.org/10.1186/s40425-019-0763-1
373 Phase 1/2 study of subcutaneously administered ALKS 4230, a novel engineered cytokine, as monotherapy and in combination with pembrolizumab, in patients with advanced solid tumors: ARTISTRY-2
https://doi.org/10.1136/jitc-2020-sitc2020.0373
Nemvaleukin alfa, a novel engineered IL-2 fusion protein, drives antitumor immunity and inhibits tumor growth in small cell lung cancer
https://doi.org/10.1136/jitc-2022-004913
nct03861793 at ClinicalTrials.govDocuments that mention this clinical trial
724 Subcutaneous nemvaleukin alfa in combination with pembrolizumab in patients with refractory solid tumors (ARTISTRY-2)
https://doi.org/10.1136/jitc-2023-sitc2023.0724
744 Assessment of safety and immunologic activity of nemvaleukin alfa in patients with advanced solid tumors treated with less frequent intravenous dosing (ARTISTRY-3)
https://doi.org/10.1136/jitc-2023-sitc2023.0744
217 Tumor microenvironment pharmacodynamic effect of nemvaleukin less frequent intravenous dosing in multiple solid tumors: results from the phase 1/2 ARTISTRY-3 study
https://doi.org/10.1136/jitc-2024-sitc2024.0217
Recommended phase 2 dose (RP2D) of nemvaleukin alfa in patients (pts) with advanced solid tumors treated with less frequent intravenous (IV) dosing (ARTISTRY-3).
https://doi.org/10.1200/jco.2024.42.16_suppl.2587
Documents that mention this clinical trial
ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy
https://doi.org/10.1136/jitc-2020-000673
724 Subcutaneous nemvaleukin alfa in combination with pembrolizumab in patients with refractory solid tumors (ARTISTRY-2)
https://doi.org/10.1136/jitc-2023-sitc2023.0724
34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019): part 1
https://doi.org/10.1186/s40425-019-0763-1
373 Phase 1/2 study of subcutaneously administered ALKS 4230, a novel engineered cytokine, as monotherapy and in combination with pembrolizumab, in patients with advanced solid tumors: ARTISTRY-2
https://doi.org/10.1136/jitc-2020-sitc2020.0373
Nemvaleukin alfa, a novel engineered IL-2 fusion protein, drives antitumor immunity and inhibits tumor growth in small cell lung cancer
https://doi.org/10.1136/jitc-2022-004913
- License Information
